The Presence and Pathogenic Roles of M( IL ‐33 + IL ‐2) Macrophages in Allergic Airway Inflammation
Allergy · 2025
DOI: 10.1111/all.16430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Han Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. Hauptthemen laut MEDLINE: Interleukin-33, Macrophages, Asthma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shenzhen Medical Research Fund.
Abstract (Originalsprache)
Background
Macrophages, one of the most abundant immune cells in the lung, have drawn great attention in allergic asthma. Currently, most studies emphasize alternative activated (M2) polarization bias. However, macrophage function in allergic asthma is still controversial. Interleukin (IL)‐9 contributes to the development and pathogenesis of allergic airway inflammation. We sought to investigate the IL‐9‐producing macrophage and its role in allergic asthma.
Methods
The model of ovalbumin (OVA)‐induced allergic airway inflammation was employed to evaluate IL‐9 production in macrophages of lung tissues. We used 22 cytokines or stimuli to screen for IL‐9‐producing mouse macrophage subset in vitro. Real‐time PCR, flow cytometry, ELISA, and RNA‐seq to explore the subset. Conditional IL‐33 receptor knockout (Lyz‐ST2KO) mice and cellular adoptive transfer experiment were used to characterize the potential roles of M(IL‐33 + IL‐2) in allergic asthma.
Results
We identified a unique pathogenic IL‐9‐producing macrophage in OVA‐induced allergic airway inflammation. We found that only IL‐33 significantly induced IL‐9 production in mouse macrophages, and IL‐2 collaborated with IL‐33 to promote IL‐9 production, referred to as M(IL‐33 + IL‐2). Importantly, human monocyte‐derived macrophages produced IL‐9 after IL‐33 and IL‐2 stimulation. Using Lyz‐ST2KO mice and adoptive transfer of M(IL‐33 + IL‐2), we found that M(IL‐33 + IL‐2) significantly promoted pathogenesis in OVA‐induced allergic airway inflammation. M(IL‐33 + IL‐2) has a distinctive gene expression profile with high expression of IL‐9, IL‐5, and IL‐13 and its polarization is dependent on JAK2‐STAT3‐IRF1 pathway.
Conclusions
The identification of M(IL‐33 + IL‐2) subset extends the diversity and heterogeneity of macrophage subsets and may offer novel therapeutic strategies for the treatment of allergic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
- Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.
- Faculty of Synthetic Biology, Shenzhen University of Advanced Technology, Shenzhen, China.
- CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
ORCID-Profile: Han Guo, Yifang Chen
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shenzhen Medical Research Fund
Zitieren
APA
Guo, H., Zhao, Y., Zhang, Z., Xu, Y., Chen, Y., Lei, T., & Zhao, Y. (2025). The Presence and Pathogenic Roles of M( IL ‐33 + IL ‐2) Macrophages in Allergic Airway Inflammation. Allergy. https://doi.org/10.1111/all.16430
Vancouver
Guo H, Zhao Y, Zhang Z, Xu Y, Chen Y, Lei T, et al. The Presence and Pathogenic Roles of M( IL ‐33 + IL ‐2) Macrophages in Allergic Airway Inflammation. Allergy. 2025. doi:10.1111/all.16430
BibTeX
@article{Guo2025,
author = {Guo, Han and Zhao, Yang and Zhang, Zhaoqi and Xu, Yanan and Chen, Yifang and Lei, Tong and Zhao, Yong},
title = {The Presence and Pathogenic Roles of M( IL ‐33 + IL ‐2) Macrophages in Allergic Airway Inflammation},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16430}
}
EUVIMED